WhaleCreep

Casdin Capital, LLC 13F holdings, Q2 2021

Hedge fundSEC filingsCompare with another fundHoldings as of 2021-06-30, filed 2021-08-16

Casdin Capital, LLC disclosed 54 US equity positions worth $3.9bn in its Q2 2021 13F filing. Its largest position is NVTA1EUR at 10.4% of the reported book, followed by BLFS and FATE. Versus Q1 2021 it opened 11 new positions, added to 8, reduced 3 and exited 5.

$3.9bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
54
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
10.4%
Largest position
The largest single position as a share of the reported equity book.
57.2%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
22
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
43
Quarters on file since Q4 2015
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2021: 11 new, 8 added, 3 reduced, 5 exited

50 of 54
NVTA1EUR INVITAE CORP–10.4%$412m12.20m0.0%held
BLFS BIOLIFE SOLUTIONS INCHealthcare8.4%$331m7.44m0.0%held
FATE FATE THERAPEUTICS INCHealthcare7.5%$295m3.40m0.0%held
EXK EXACT SCIENCES CORPBasic Materials7.4%$293m2.36m0.0%held
VERVE THERAPEUTICS INC no ticker–4.6%$183m3.04m–new
PACB PACIFIC BIOSCIENCES CALIF INHealthcare4.4%$175m5.00m0.0%held
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare4.3%$170m1.00m+14%added
2655787D BLUEPRINT MEDICINES CORP–3.5%$136m1.55m0.0%held
TWST TWIST BIOSCIENCE CORPHealthcare3.4%$133m1.00m0.0%held
DNLI DENALI THERAPEUTICS INCHealthcare3.2%$126m1.61m0.0%held
RLAY RELAY THERAPEUTICS INCHealthcare3.1%$123m3.38m0.0%held
AGIO AGIOS PHARMACEUTICALS INCHealthcare3.0%$119m2.17m0.0%held
CDNA CAREDX INCHealthcare2.8%$109m1.19m0.0%held
BEAM BEAM THERAPEUTICS INCHealthcare2.7%$105m818,8200.0%held
CDXS CODEXIS INCHealthcare2.5%$98.1m4.33m0.0%held
IPSC CENTURY THERAPEUTICS INCHealthcare2.4%$94.1m3.21m–new
SINGULAR GENOMICS SYSTEMS IN no ticker–1.9%$74.0m2.69m–new
RVMD REVOLUTION MEDICINES INCHealthcare1.9%$73.2m2.31m+25%added
DMTKQ DERMTECH INC–1.8%$72.5m1.75m0.0%held
SRPT SAREPTA THERAPEUTICS INCHealthcare1.7%$68.8m885,000+61%added
ADPT ADAPTIVE BIOTECHNOLOGIES CORHealthcare1.5%$58.8m1.44m+25%added
ONC BEIGENE LTDHealthcare1.3%$51.5m150,0000.0%held
AMRSEUR AMYRIS INC–1.2%$49.1m3.00m–new
GBTUSD GLOBAL BLOOD THERAPEUTICS IN–1.2%$45.9m1.31m+46%added
CNST CONSTELLATION PHARMCETICLS I–1.2%$45.3m1.34m−26%reduced
GBIOGBX GENERATION BIO CO–1.1%$43.3m1.61m0.0%held
CRSP CRISPR THERAPEUTICS AGHealthcare1.1%$43.1m266,4300.0%held
ALEC ALECTOR INCHealthcare0.9%$34.4m1.65m0.0%held
ZLAB ZAI LAB LTDHealthcare0.9%$33.6m190,0000.0%held
MAGENTA THERAPEUTICS INC no ticker–0.8%$32.7m3.35m0.0%held
23ANDME HOLDING CO no ticker–0.8%$32.0m2.74m–new
ALLO ALLOGENE THERAPEUTICS INCHealthcare0.8%$31.9m1.23m−5.8%reduced
FDMT 4D MOLECULAR THERAPEUTICS INHealthcare0.7%$26.9m1.12m+12%added
NEO NEOGENOMICS INCHealthcare0.6%$22.1m488,889–new
GLUE MONTE ROSA THERAPEUTICS INCHealthcare0.6%$21.8m960,883–new
SNDX SYNDAX PHARMACEUTICALS INCHealthcare0.5%$20.6m1.20m+20%added
RXRX RECURSION PHARMACEUTICALS INHealthcare0.5%$20.0m548,156–new
MASS 908 DEVICES INC–0.4%$15.8m406,5020.0%held
ORTXUSD ORCHARD THERAPEUTICS PLC–0.4%$14.1m3.22m0.0%held
KRON1USD KRONOS BIO INC–0.4%$14.0m583,4360.0%held
FULC FULCRUM THERAPEUTICS INCHealthcare0.3%$12.1m1.15m−7.0%reduced
ORIC ORIC PHARMACEUTICALS INCHealthcare0.3%$10.6m601,5150.0%held
DECIBEL THERAPEUTICS INC no ticker–0.3%$10.1m1.17m+2.2%added
CLOV CLOVER HEALTH INVESTMENTS COHealthcare0.2%$9.7m726,5110.0%held
BLIUSD PHENOMEX INC–0.2%$9.0m200,0000.0%held
TKNO ALPHA TEKNOVA INC–0.2%$7.1m300,000–new
SGMOQ SANGAMO THERAPEUTICS INCHealthcare0.2%$6.6m550,0000.0%held
TURNING POINT THERAPEUTICS I no ticker–0.1%$5.9m75,0000.0%held
NAUT NAUTILUS BIOTECHNOLOGY INC–0.1%$5.0m500,000–new
SEER SEER INCHealthcare0.1%$4.9m150,0000.0%held

Exited since Q1 2021

5 rows
BNR BURNING ROCK BIOTECH LTD0.7%$22.8m
ADVMCHF ADVERUM BIOTECHNOLOGIES INC0.6%$21.8m
TSHA TAYSHA GENE THERAPIES INC0.5%$16.7m
DYN DYNE THERAPEUTICS INC0.3%$9.5m
32W CODIAK BIOSCIENCES INC0.03%$1.2m

Sector mix

  • Healthcare61.9%
  • Unclassified30.7%
  • Basic Materials7.4%

Book over time

Every quarter on file (43)
QuarterPositionsEquity book
Q2 202643$2.0bn
Q1 202640$1.3bn
Q4 202538$1.6bn
Q3 202532$1.2bn
Q2 202533$1.1bn
Q1 202544$1.2bn
Q4 202438$1.5bn
Q3 202435$1.5bn
Q2 202438$1.3bn
Q1 202436$1.3bn
Q4 202336$1.0bn
Q3 202338$897m
Q2 202341$1.1bn
Q1 202340$1.2bn
Q4 202244$1.3bn
Q3 202236$1.5bn
Q2 202240$1.2bn
Q1 202247$2.2bn
Q4 202153$3.5bn
Q3 202153$4.0bn
Q2 202154$3.9bn
Q1 202148$3.4bn
Q4 202050$3.4bn
Q3 202045$2.2bn
Q2 202042$1.7bn
Q1 202038$942m
Q4 201931$1.1bn
Q3 201933$966m
Q2 201931$1.1bn
Q1 201929$910m
Q4 201831$585m
Q3 201834$814m
Q2 201832$709m
Q1 201830$565m
Q4 201726$409m
Q3 201726$354m
Q2 201731$250m
Q1 201729$170m
Q4 201625$121m
Q3 201626$123m
Q2 201624$95.7m
Q1 201625$84.5m
Q4 201527$107m

Where Casdin Capital, LLC was early

41 rows
EDIT EDITAS MEDICINE INCQ1 20162 of 963.5%3.5%15Held at last filing, Q2 2026−91%
ONC BEIGENE LTDQ1 20169 of 1041.1%2.1%16Exited by Q2 2025+829%
EVH EVOLENT HEALTH INCQ2 20161 of 1304.8%7.7%12Exited by Q2 2019−34%
T8S TESARO INCQ2 20168 of 831.8%2.7%4Exited by Q4 2017+54%
MDRX ALLSCRIPTS HEALTHCARE SOLUTNQ3 20168 of 962.1%2.4%3Exited by Q2 2017−3.7%
CDXS CODEXIS INCQ1 20172 of 801.9%8.1%29Exited by Q3 2025−49%
PACB PACIFIC BIOSCIENCES CALIF INQ1 20173 of 1182.1%5.1%21Held at last filing, Q2 2026−68%
SGMOQ SANGAMO THERAPEUTICS INCQ1 20173 of 852.6%5.9%19Exited by Q3 2022−20%
FATE FATE THERAPEUTICS INCQ2 20174 of 1070.7%8.3%27Exited by Q1 2024+15%
CRSP CRISPR THERAPEUTICS AGQ1 20181 of 1201.1%1.8%11Exited by Q1 2022+66%
ZLAB ZAI LAB LTDQ1 20186 of 990.5%1.0%11Exited by Q2 2022+106%
BLFS BIOLIFE SOLUTIONS INCQ2 20181 of 781.6%16.3%33Held at last filing, Q2 2026+148%
CDNA CAREDX INCQ2 20186 of 1030.3%3.0%16Exited by Q2 2022+202%
CNST CONSTELLATION PHARMCETICLS IQ3 20181 of 721.1%5.3%12Exited by Q3 2021–
2JQ GRITSTONE ONCOLOGY INCQ3 20182 of 621.3%1.9%8Exited by Q3 2020−53%
SRPT SAREPTA THERAPEUTICS INCQ3 201814 of 1820.8%13.7%29Held at last filing, Q2 2026−89%
DNLI DENALI THERAPEUTICS INCQ4 20182 of 1040.4%3.7%31Held at last filing, Q2 2026+24%
ALEC ALECTOR INCQ1 20194 of 870.7%2.8%12Exited by Q1 2022+10%
TWST TWIST BIOSCIENCE CORPQ2 20192 of 990.8%4.2%17Exited by Q3 2023−29%
ADPT ADAPTIVE BIOTECHNOLOGIES CORQ2 20194 of 1301.9%2.3%12Exited by Q2 2022−71%
FULC FULCRUM THERAPEUTICS INCQ3 20191 of 950.6%1.9%8Exited by Q3 2021+58%
RVMD REVOLUTION MEDICINES INCQ1 20201 of 1643.1%24.2%26Held at last filing, Q2 2026+755%
DMTKQ DERMTECH INCQ1 20202 of 470.6%2.6%9Exited by Q2 2022+31%
ALLO ALLOGENE THERAPEUTICS INCQ1 20204 of 941.0%1.6%8Exited by Q1 2022−23%
GBIOGBX GENERATION BIO COQ2 20201 of 482.0%2.2%8Exited by Q2 2022−65%
RLAY RELAY THERAPEUTICS INCQ3 20201 of 1117.3%15.0%24Held at last filing, Q2 2026−56%
FDMT 4D MOLECULAR THERAPEUTICS INQ4 20201 of 941.0%2.1%16Exited by Q1 2025−87%
BEAM BEAM THERAPEUTICS INCQ4 20203 of 981.1%3.2%23Held at last filing, Q2 2026−58%
ABCL ABCELLERA BIOLOGICS INCQ4 20207 of 870.2%1.8%9Exited by Q2 2024−89%
IPSC CENTURY THERAPEUTICS INCQ2 20213 of 512.4%2.4%21Held at last filing, Q2 2026−92%
TNYA TENAYA THERAPEUTICS INCQ3 20211 of 531.8%3.3%20Held at last filing, Q2 2026−96%
ABSI ABSCI CORPORATIONQ3 20212 of 762.2%2.9%20Held at last filing, Q2 2026−0.3%
MXCT MAXCYTE INCQ3 20212 of 634.3%5.6%9Exited by Q4 2023−74%
TNGX TANGO THERAPEUTICS INCQ3 20212 of 1031.8%1.9%13Exited by Q2 2025−89%
WGS GENEDX HOLDINGS CORPQ3 20215 of 1040.9%29.5%20Held at last filing, Q2 2026−73%
TSVT* 2SEVENTY BIO INCQ1 20224 of 700.5%1.8%13Exited by Q2 2025−71%
PLRX PLIANT THERAPEUTICS INCQ3 20228 of 1031.0%3.7%8Exited by Q3 2024−49%
PRME PRIME MEDICINE INCQ4 20223 of 621.1%1.5%15Held at last filing, Q2 2026−80%
GPCR STRUCTURE THERAPEUTICS INCQ1 20231 of 1141.3%6.9%14Held at last filing, Q2 2026+126%
NGNE NEUROGENE INCQ4 20232 of 451.0%2.4%11Held at last filing, Q2 2026+62%
MAZE MAZE THERAPEUTICS INCQ1 20259 of 820.9%2.0%6Held at last filing, Q2 2026+171%

Concentration and tenure

12.9%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
65.0%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
3
Median completed holding, quarters